Losartan and its metabolite E3174 modify cardiac delayed rectifier K+ currents

Circulation

Volumn 101, Issue 10, 2000, Pages 1199-1205

  Caballero, Ricardo ^a   Delpón, Eva ^a   Valenzuela, Carmen ^a   Longobardo, Mónica ^a   Tamargo, Juan ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

E3174; Electrophysiology; Ion channels; Losartan; Myocytes

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; LOSARTAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTROPHYSIOLOGY; GUINEA PIG; HEART MUSCLE CELL; MEMBRANE POTENTIAL; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; REPOLARIZATION;

EID: 0034646388     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.10.1199     Document Type: Article

References (15)

1. Griendling KK, Lassègue B, Alexander W. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol. 1996;36: 281-306.
2. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet. 1995;386:1403-1407.
3. Pitt B, Segal R, Martínez F, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, on behalf of ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
4. Timmermans PBMWM, Wong P, Chiu A, Herblin W, Benfield P, Carini D, Lee R, Wexler R, Saye JA, Smith R. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-251.
5. Fleetwood G, Boutinet S, Meier M, Wood JM. Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart. J Cardiovasc Pharmacol. 1991; 17:351-356.
6. Thomas G, Ferrier G, Howlett S. Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. J Pharmacol Exp Ther. 1996;278:1090-1098.
7. Timmermans PBMWM, Smith RD. Angiotensin II receptor subtypes: selective antagonist and functional correlates. Eur Heart J. 1994;15: 79-87.
8. Pérez O, Valenzuela C, Delpón E, Tamargo J. Electrophysiological effects of CI-980, a tubulin binding agent, on guinea-pig papillary muscles. Br J Pharmacol. 1997;120:187-192.
9. + current in guinea pig ventricular myocytes: voltage-independent and time-dependent block of the slowly activating component. Circ Res. 1995;76:223-235.
10. Snyders DJ, Tamkun MM, Bennett PB. A rapidly activating and slowly inactivating potassium channel cloned from human heart: functional analysis after stable mammalian cell culture expression. J Gen Physiol. 1993;101:513-543.
11. Valenzuela C, Delpón E, Franqueza L, Gay P, Pérez O, Tamargo J, Snyders DJ. Class III antiarrhythmic effects of zatebradine: time-, state-, and voltage-dependent block of hKv1.5 channels. Circulation. 1996;94: 562-570.
12. Kr potassium channel. Cell. 1995;81:299-307.
13. Rich T, Snyders DJ. Evidence for multiple open and inactivated states of the hKv1.5 delayed rectifier. Biophys J. 1998;75:183-195.
14. Brooksky P, Robinson PJ, Segal R, Klinger GH, Pitt B, Cowley AJC, on behalf of ELITE Study Group. Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. Lancet. 1999;354: 395-396.
15. Courtemanche M, Ramírez RJ, Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc Res. 1999;42:477-489.